Bayer Xaerelto study shows “encouraging results”

Bayer’s phase II study of its Xarelto (rivaroxaban) novel oral anticoagulant has revealed "encouraging results", the company has announced.

Tests in almost 3,500 patients with acute coronary syndrome (ACS) showed the drug was associated with an observed 21 per cent Relative Risk Reduction (RRR) for the primary efficacy endpoint – death, stroke myocardial infarction (MI) or severe recurrent ischemia requiring revascularisation.

For the secondary endpoint of death, stroke or MI the RRR was observed at 31 per cent.

The phase II data was presented yesterday (November 10th) at an American Heart Association meeting in New Orleans, while a phase III trial for the secondary prevention of ACS is planned for later this year.

Dr C Michael Gibson, director of the TIMI Data Coordinating Centre at Harvard Medical School, explained the results: "The additional benefit of rivaroxaban over placebo in this study, given on a background of standard antiplatelet therapy, highlights the unmet medical need of this patient population."

People in science sales jobs may also be interested in Bayer’s Contour blood glucose meter, which received positive feedback from researchers recently.